A phase II trial of Doxorubicin HCl Liposome Injection in patients with advanced pancreatic adenocarcinoma

Gary K. Schwartz, Ephraim S. Casper

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

We conducted a phase II study with doxorubicin encapsulated in a liposomal preparation (Doxorubicin HCl Liposome Injection) at a dose of 75 mg/m2 administered as a one hour infusion once every three weeks. Sixteen patients were entered to the trial and 15 are evaluable for response. Hematologic toxicity was significant. The median white blood count was 1.6×103/μl (range: 0.1–9.5), median absolute neutrophil count 0.6×103/μl (range: 0–5.8) and median platelet count was 142.0×103/μl (range: 20–327). Gastrointestinal toxicity was generally mild. Despite two minor responses in liver metastases with a significant decrease in CEA in one of these patients, no major responses were observed, excluding with 95% confidence, a response rate in excess of 20%.

Original languageEnglish
Pages (from-to)77-82
Number of pages6
JournalInvestigational New Drugs
Volume13
Issue number1
DOIs
StatePublished - Mar 1995
Externally publishedYes

Keywords

  • Doxorubicin HCl Liposome Injection
  • pancreatic cancer
  • phase II study

Fingerprint

Dive into the research topics of 'A phase II trial of Doxorubicin HCl Liposome Injection in patients with advanced pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Cite this